{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:21Z","timestamp":1707524721700},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,19]]},"DOI":"10.7759\/cureus.28156","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:27:38Z","timestamp":1660897658000},"source":"Crossref","is-referenced-by-count":0,"title":["Dabrafenib Plus Trametinib: An Impressive Response in an Adult Patient With BRAF V600E-Mutated and Isocitrate Dehydrogenase (IDH) Wild-Type Glioma"],"prefix":"10.7759","author":[{"given":"In\u00eas N","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/ijpm.ijpm_48_22","article-title":"World Health Organization classification of tumors of the central nervous system 5th Edition (WHO CNS5): what's new?","volume":"65","author":"Mahajan S","year":"2022","unstructured":"Mahajan S, Suri V, Sahu S, Sharma MC, Sarkar C. World Health Organization classification of tumors of the central nervous system 5th Edition (WHO CNS5): what's new?. Indian J Pathol Microbiol. 2022, 65:S5-S13. 10.4103\/ijpm.ijpm_48_22","journal-title":"Indian J Pathol Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-640","article-title":"Overview of prognostic factors in adult gliomas","volume":"10","author":"Sharma A","year":"2021","unstructured":"Sharma A, Graber JJ. Overview of prognostic factors in adult gliomas. Ann Palliat Med. 2021, 10:863-74. 10.21037\/apm-20-640","journal-title":"Ann Palliat Med"},{"key":"ref3","article-title":"BRAF alterations in primary brain tumors","volume":"26","author":"Maraka S","year":"2018","unstructured":"Maraka S, Janku F. BRAF alterations in primary brain tumors. Discov Med. 2018, 26:51-60.","journal-title":"Discov Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab247","article-title":"Prevalence of BRAFV600 in glioma and use of BRAF inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review","volume":"24","author":"Andrews LJ","year":"2022","unstructured":"Andrews LJ, Thornton ZA, Saincher SS, et al.. Prevalence of BRAFV600 in glioma and use of BRAF inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro Oncol. 2022, 24:528-40. 10.1093\/neuonc\/noab247","journal-title":"Neuro Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1837-8","article-title":"Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations","volume":"136","author":"Reinhardt A","year":"2018","unstructured":"Reinhardt A, Stichel D, Schrimpf D, et al.. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations. Acta Neuropathol. 2018, 136:273-91. 10.1007\/s00401-018-1837-8","journal-title":"Acta Neuropathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2020-0027","article-title":"Adult pilocytic astrocytoma in the molecular era: a comprehensive review","volume":"10","author":"Gregory TA","year":"2021","unstructured":"Gregory TA, Chumbley LB, Henson JW, Theeler BJ. Adult pilocytic astrocytoma in the molecular era: a comprehensive review. CNS Oncol. 2021, 10:CNS68. 10.2217\/cns-2020-0027","journal-title":"CNS Oncol"},{"key":"ref7","article-title":"Pilocytic Astrocytoma","author":"Knight J","year":"2021","unstructured":"Knight J, De Jesus O. Pilocytic Astrocytoma. StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2021."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen PY","year":"2022","unstructured":"Wen PY, Stein A, van den Bent M, et al.. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022, 23:53-64. 10.1016\/S1470-2045(21)00578-7","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta A","year":"2017","unstructured":"Lassaletta A, Zapotocky M, Mistry M, et al.. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. 2017, 35:2934-41. 10.1200\/JCO.2016.71.8726","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00298","article-title":"Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition","volume":"4","author":"Nobre L","year":"2020","unstructured":"Nobre L, Zapotocky M, Ramaswamy V, et al.. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precis Oncol. 2020, 4:10.1200\/PO.19.00298","journal-title":"JCO Precis Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/102711-dabrafenib-plus-trametinib-an-impressive-response-in-an-adult-patient-with-braf-v600e-mutated-and-isocitrate-dehydrogenase-idh-wild-type-glioma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:15Z","timestamp":1707507495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/102711-dabrafenib-plus-trametinib-an-impressive-response-in-an-adult-patient-with-braf-v600e-mutated-and-isocitrate-dehydrogenase-idh-wild-type-glioma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.28156","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,19]]}}}